A glimpse at HDL-based therapy for atherosclerosis.

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Translational Therapeutics

Background:

• Atherosclerosis is a major cause of cardiovascular disease, often managed with low-density lipoprotein (LDL) lowering therapies.
• Current treatments primarily focus on reducing LDL cholesterol, with limited options for directly targeting HDL or atherosclerotic plaque regression.
• High-density lipoprotein (HDL) plays a crucial role in reverse cholesterol transport and possesses anti-atherogenic properties.

Purpose of the Study:

• To evaluate the efficacy of a novel HDL-based therapy in reducing atherosclerotic plaque volume.
• To explore a new therapeutic approach complementary to existing LDL-lowering strategies.
• To assess the potential of apolipoprotein A-I Milano (apoA-I Milano) in altering the atherosclerotic process.

Main Methods:

• Pilot study involving the infusion of a recombinant form of apoA-I Milano, a naturally occurring mutant human apolipoprotein.
• Treatment administered over a 6-week period.
• Assessment of changes in atherosclerotic plaque volume.

Main Results:

• The apoA-I Milano infusion resulted in a significant reduction in atherosclerotic plaque volume within 6 weeks.
• The HDL-based treatment demonstrated a potential to alter the atherosclerotic process.
• This pilot study suggests a new therapeutic avenue for atherosclerosis management.

Conclusions:

• HDL-based therapy with apoA-I Milano shows promise as a complementary treatment for atherosclerosis.
• Further replication studies with larger patient cohorts and clinical endpoints are essential.
• Modification of HDL represents a viable strategy for targeting atherosclerotic plaque regression.